Levemir is a drug that is approved to treat both type 1 and type 2 diabetes. This medication is a long-acting insulin, and works by providing a steady level of insulin to help control blood sugar levels throughout the day. Levemir comes in injectable form and is typically used once or twice a day. Possible side effects include low blood sugar levels and skin reactions at the injection site.
Studies have shown that once- or twice-daily Levemir works similarly to once- or twice-daily NPH insulin (an intermediate-acting insulin) in adults and children with type 1 diabetes and in adults with type 2 diabetes. Studies have also shown that twice-daily Levemir works similarly to once-daily insulin glargine (Lantus®), a long-acting insulin, in adults with type 1 diabetes.
More importantly, studies seem to suggest that people may gain less weight with Levemir, compared to those using Lantus or NPH insulin, although further research is necessary to confirm these findings.
Written by/reviewed by: Kristi Monson, PharmD;Arthur Schoenstadt, MD
Last reviewed by: KristiMonson, PharmD;
List of references (click here):
Levemir [package insert]. Plainsboro, NJ: Novo Nordisk;2013 October.
Food and Drug Administration, Center for Drug Evaluation and Research. Electronic orange book: Approved drug products with therapeutic equivalence evaluations. FDA Web site. Available at: http://www.fda.gov/cder/ob/. Accessed April 26, 2008.
Briggs GG, Freeman RK, Yaffe SJ. Drugs in Pregnancy and Lactation. 7th ed. Philadelphia (PA): Lippincott Williams & Wilkins;2005.
eMedTV serves only as an informational resource. This site does not dispense medical advice or advice of any kind.
Site users seeking medical advice about their specific situation should consult with their own physician. Click